1. Home
  2. HLNE vs CRNX Comparison

HLNE vs CRNX Comparison

Compare HLNE & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Lane Incorporated

HLNE

Hamilton Lane Incorporated

HOLD

Current Price

$83.16

Market Cap

3.6B

Sector

Finance

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$83.73

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HLNE
CRNX
Founded
1991
2008
Country
United States
United States
Employees
785
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.9B
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
HLNE
CRNX
Price
$83.16
$83.73
Analyst Decision
Buy
Strong Buy
Analyst Count
9
8
Target Price
$156.78
$76.75
AVG Volume (30 Days)
797.1K
6.8M
Earning Date
05-21-2026
05-07-2026
Dividend Yield
2.44%
N/A
EPS Growth
41.64
N/A
EPS
3.98
N/A
Revenue
$758,993,000.00
$1,039,000.00
Revenue This Year
$9.69
$720.10
Revenue Next Year
$15.81
$184.67
P/E Ratio
$20.39
N/A
Revenue Growth
6.46
N/A
52 Week Low
$71.88
$25.83
52 Week High
$161.13
$84.00

Technical Indicators

Market Signals
Indicator
HLNE
CRNX
Relative Strength Index (RSI) 51.78 92.07
Support Level $76.36 $33.50
Resistance Level $87.97 N/A
Average True Range (ATR) 3.07 0.18
MACD 0.25 -0.10
Stochastic Oscillator 47.75 53.51

Price Performance

Historical Comparison
HLNE
CRNX

About HLNE Hamilton Lane Incorporated

Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: